Boc-Lys(Boc)-OHCAS# 2483-46-7 |
- Cisplatin
Catalog No.:BCN1552
CAS No.:14283-03-5
- Z-VAD-FMK
Catalog No.:BCC1126
CAS No.:187389-52-2
- Z-WEHD-FMK
Catalog No.:BCC1139
CAS No.:210345-00-9
- Z-LEHD-FMK
Catalog No.:BCC5117
CAS No.:210345-04-3
- AZ 10417808
Catalog No.:BCC2356
CAS No.:331645-84-2
- Apoptosis Activator 2
Catalog No.:BCC2099
CAS No.:79183-19-0
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 2483-46-7 | SDF | Download SDF |
PubChem ID | 294904 | Appearance | Powder |
Formula | C16H30N2O6 | M.Wt | 346.4 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
Chemical Name | 2,6-bis[(2-methylpropan-2-yl)oxycarbonylamino]hexanoic acid | ||
SMILES | CC(C)(C)OC(=O)NCCCCC(C(=O)O)NC(=O)OC(C)(C)C | ||
Standard InChIKey | FBVSXKMMQOZUNU-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C16H30N2O6/c1-15(2,3)23-13(21)17-10-8-7-9-11(12(19)20)18-14(22)24-16(4,5)6/h11H,7-10H2,1-6H3,(H,17,21)(H,18,22)(H,19,20) | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Boc-Lys(Boc)-OH Dilution Calculator
Boc-Lys(Boc)-OH Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.8868 mL | 14.4342 mL | 28.8684 mL | 57.7367 mL | 72.1709 mL |
5 mM | 0.5774 mL | 2.8868 mL | 5.7737 mL | 11.5473 mL | 14.4342 mL |
10 mM | 0.2887 mL | 1.4434 mL | 2.8868 mL | 5.7737 mL | 7.2171 mL |
50 mM | 0.0577 mL | 0.2887 mL | 0.5774 mL | 1.1547 mL | 1.4434 mL |
100 mM | 0.0289 mL | 0.1443 mL | 0.2887 mL | 0.5774 mL | 0.7217 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Boc-Lys(Boc)-OH
- Laquinimod (ABR-215062)
Catalog No.:BCC3802
CAS No.:248281-84-7
- Agmatine sulfate
Catalog No.:BCC6813
CAS No.:2482-00-0
- Reserpinine
Catalog No.:BCN3490
CAS No.:24815-24-5
- H-Cys(tBu)-OH.HCl
Catalog No.:BCC2910
CAS No.:2481-09-6
- (-)-Epiafzelechin
Catalog No.:BCN5114
CAS No.:24808-04-6
- Boc-Orn(Z)-OH
Catalog No.:BCC3430
CAS No.:2480-93-5
- N2-Methyl-L-arginine
Catalog No.:BCC6032
CAS No.:2480-28-6
- H-N-Me-Ser-OH.HCl
Catalog No.:BCC3352
CAS No.:2480-26-4
- N-Me-Val-OH.HCl
Catalog No.:BCC2612
CAS No.:2480-23-1
- Estriol 3-glucuronide
Catalog No.:BCN2239
CAS No.:2479-91-6
- 1,3-Bis(4-aminophenoxy)benzene
Catalog No.:BCC8418
CAS No.:2479-46-1
- Beta-Peltoboykinolic acid
Catalog No.:BCN6635
CAS No.:24778-48-1
- Azaphen
Catalog No.:BCC1390
CAS No.:24853-80-3
- Erlotinib mesylate
Catalog No.:BCC1558
CAS No.:248594-19-6
- Boc-Met-OH
Catalog No.:BCC3424
CAS No.:2488-15-5
- Mesembrine
Catalog No.:BCN3668
CAS No.:24880-43-1
- Bakkenolide III
Catalog No.:BCN7245
CAS No.:24909-95-3
- H-Met-OMe. HCl
Catalog No.:BCC2995
CAS No.:2491-18-1
- H-Ala-OMe.HCl
Catalog No.:BCC3192
CAS No.:2491-20-5
- beta-Isosparteine
Catalog No.:BCN2326
CAS No.:24915-04-6
- Sarracine
Catalog No.:BCN2021
CAS No.:2492-09-3
- Ethyl 3-cyclopropyl-3-oxopropanoate
Catalog No.:BCC8974
CAS No.:24922-02-9
- Varenicline
Catalog No.:BCC4155
CAS No.:249296-44-4
- Poly(I:C)
Catalog No.:BCC6138
CAS No.:24939-03-5
Monitoring histone deacetylase inhibition in vivo: noninvasive magnetic resonance spectroscopy method.[Pubmed:18706291]
Mol Imaging. 2008 Mar-Apr;7(2):92-100.
Histone deacetylase inhibitors (HDACis) are emerging as promising and selective antitumor agents. However, HDACis can lead to tumor stasis rather than shrinkage, in which case, traditional imaging methods are not adequate to monitor response. Consequently, novel approaches are needed. We have shown in cells that (19)F magnetic resonance spectroscopy (MRS)-detectable levels of the HDAC substrate Boc-Lys-TFA-OH (BLT) are inversely correlated with HDAC activity. We extended our investigations to a tumor xenograft model. Following intraperitoneal injection of BLT, its accumulation within the tumor was monitored by in vivo (19)F MRS. In animals treated with the HDACi suberoylanilide hydroxamic acid (SAHA), tumoral BLT levels were higher by 77% and 132% on days 2 and 7 of treatment compared with pretreatment levels (n = 6; p < .05). In contrast, tumoral BLT levels remained unchanged in control animals and in normal tissue. Thus, (19)F MRS of BLT detected the effect of HDACi treatment as early as day 2 of treatment. Importantly, tumor size confirmed that SAHA treatment leads to inhibition of tumor growth. However, difference in tumor size reached significance only on day 6 of treatment. Thus, this work identifies BLT as a potential molecular imaging agent for the early noninvasive MRS detection of HDAC inhibition in vivo.
Inhibition of histone-deacetylase activity by short-chain fatty acids and some polyphenol metabolites formed in the colon.[Pubmed:18061431]
J Nutr Biochem. 2008 Sep;19(9):587-93.
Colorectal cancer is the most abundant cause of cancer mortality in the Western world. Nutrition and the microbial flora are considered to have a marked influence on the risk of colorectal cancer, the formation of butyrate and other short-chain fatty acids (SCFAs) possibly playing a major role as chemopreventive products of microbial fermentation in the colon. In this study, we investigated the effects of butyrate, other SCFAs, and of a number of phenolic SCFA and trans-cinnamic acid derivatives formed during the intestinal degradation of polyphenolic constituents of fruits and vegetables on global histone deacetylase (HDAC) activity in nuclear extracts from colon carcinoma cell cultures using tert-butoxycarbonyl-lysine (acetylated)-4-amino-7-methylcoumarin (Boc-Lys(Ac)-AMC) as substrate. Inhibition of HDAC activity, e.g., by butyrate, is related to a suppression of malignant transformation and a stimulation of apoptosis of precancerous colonic cells. In nuclear extracts from HT-29 human colon carcinoma cells, butyrate was found to be the most potent HDAC inhibitor (IC50=0.09 mM), while other SCFAs such as propionate were less potent. In the same assay, p-coumaric acid (IC50=0.19 mM), 3-(4-OH-phenyl)-propionate (IC50=0.62 mM) and caffeic acid (IC50=0.85 mM) were the most potent HDAC inhibitors among the polyphenol metabolites tested. Interestingly, butyrate was also the most potent HDAC inhibitor in a whole-cell HeLa Mad 38-based reporter gene assay, while all polyphenol metabolites and all other SCFAs tested were much less potent; some were completely inactive. The findings suggest that butyrate plays an outstanding role as endogenous HDAC inhibitor in the colon, and that other SCFAs and HDAC-inhibitory polyphenol metabolites present in the colon seem to play a much smaller role, probably because of their limited levels, their marked cytotoxicity and/or their limited intracellular availability.
Synthesis and biological activity of homoarginine-containing opioid peptides.[Pubmed:16967435]
J Pept Sci. 2007 Jan;13(1):27-30.
Two tris-alkoxycarbonyl homoarginine derivatives, Boc-Har{omega,omega'-[Z(2Br)]2}-OH and Boc-Har{omega,omega'-[Z(2Cl)]2}-OH, were prepared by guanidinylation of Boc-Lys-OH, and used for the synthesis of neo-endorphins and dynorphins. The results were compared with that obtained in the synthesis in which Boc-Lys(Fmoc)-OH was incorporated into the peptide chain, and after removing Fmoc protection, the resulting peptide-resin was guanidinylated with N,N'-[Z(2Br)]2- or N,N'-[Z(2Cl)]2-S-methylisourea. The peptides were tested in the guinea-pig ileum (GPI) and mouse vas deferens (MVD) assays. The results indicated that replacement of Arg by Har may be a good avenue for the design of biologically active peptides with increased resistance to degradation by trypsin-like enzymes.
Synthesis, cleavage profile, and antitumor efficacy of an albumin-binding prodrug of methotrexate that is cleaved by plasmin and cathepsin B.[Pubmed:17628030]
Arch Pharm (Weinheim). 2007 Aug;340(8):389-95.
Cathepsin B and plasmin are intra- or extracellular proteases that are overexpressed by several solid tumors. In order to exploit both proteases as molecular targets for tumor-specific cleavage of prodrugs, an albumin-binding formulation of methotrexate was developed that incorporated the peptide sequence D-Ala-Phe-Lys as the protease substrate. Albumin is a suitable carrier for cytostatic agents due to passive accumulation in solid tumors. Synthesis was performed by coupling the peptide linker EMC-D-Ala-Phe-Lys(Boc)-Lys-OH (EMC = epsilon-maleimidocaproic acid) to the gamma-COOH group of alpha-tert-butyl protected methotrexate. After cleavage of the protective groups and purification on reverse phase HPLC, a highly water-soluble methotrexate-peptide derivative was obtained that binds rapidly and selectively to human serum albumin. The albumin-bound form of the prodrug was shown to be efficiently cleaved by cathepsin B and plasmin as well as in an ovarian carcinoma homogenate (OVCAR-3) liberating a methotrexate-lysine derivative. In an OVCAR-3 xenograft model, the prodrug at a dose of 4x15 mg/kg methotrexate equivalents demonstrated distinctly superior antitumor efficacy compared to free methotrexate at a dose of 4x100 mg/kg [T/C(%) for MTX = 69; T/C(%) for MTX prodrug = 29]. The data provide a further proof of concept for the development of albumin-binding, enzymatically cleavable prodrugs of anticancer drugs.
Detection of histone deacetylase inhibition by noninvasive magnetic resonance spectroscopy.[Pubmed:16731766]
Mol Cancer Ther. 2006 May;5(5):1325-34.
Histone deacetylase (HDAC) inhibitors are new and promising antineoplastic agents. Current methods for monitoring early response rely on invasive biopsies or indirect blood-derived markers. Our goal was to develop a magnetic resonance spectroscopy (MRS)-based method to detect HDAC inhibition. The fluorinated lysine derivative Boc-Lys-(Tfa)-OH (BLT) was investigated as a (19)F MRS molecular marker of HDAC activity together with (31)P MRS of endogenous metabolites. In silico modeling of the BLT-HDAC interaction and in vitro MRS studies of BLT cleavage by HDAC confirmed BLT as a HDAC substrate. BLT did not affect cell viability or HDAC activity in PC3 prostate cancer cells. PC3 cells were treated, in the presence of BLT, with the HDAC inhibitor p-fluoro-suberoylanilide hydroxamic acid (FSAHA) over the range of 0 to 10 micromol/L, and HDAC activity and MRS spectra were monitored. Following FSAHA treatment, HDAC activity dropped, reaching 53% of control at 10 micromol/L FSAHA. In parallel, a steady increase in intracellular BLT from 14 to 32 fmol/cell was observed. BLT levels negatively correlated with HDAC activity consistent with higher levels of uncleaved BLT in cells with inhibited HDAC. Phosphocholine, detected by (31)P MRS, increased from 7 to 16 fmol/cell following treatment with FSAHA and also negatively correlated with HDAC activity. Increased phosphocholine is probably due to heat shock protein 90 inhibition as indicated by depletion of client proteins. In summary, (19)F MRS of BLT, combined with (31)P MRS, can be used to monitor HDAC activity in cells. In principle, this could be applied in vivo to noninvasively monitor HDAC activity.